Current Treatment in Advanced Renal Cell Carcinoma (RCC): Impact of Targeted Therapies in the Management of RCC{A figure is presented}

European Urology, Supplements

Volumn 6, Issue 7, 2007, Pages 484-491

  Bellmunt, Joaquim ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Advanced renal cell carcinoma; Sorafenib; Sunitinib; Targeted therapies; Temsirolimus

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; BEVACIZUMAB; CETUXIMAB; CYTOKINE; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; EVEROLIMUS; FLUOROURACIL; GEFITINIB; INTERLEUKIN 2; LAPATINIB; MAMMALIAN TARGET OF RAPAMYCIN; PANITUMUMAB; PAZOPANIB; PLACEBO; PLATELET DERIVED GROWTH FACTOR; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN;

ADVANCED CANCER; ANEMIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DRUG ACTIVITY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FLU LIKE SYNDROME; HAIR DISCOLORATION; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LOADING DRUG DOSE; LOW DRUG DOSE; METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN TARGETING; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; STOMATITIS; TUMOR CELL; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT;

EID: 33846821883     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2007.01.018     Document Type: Review

References (51)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2006. CA Cancer J Clin 56 (2006) 106-130
2. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
3. Kish J.A., Wolf M., Crawford E.D., et al. Evaluation of low dose continuous infusion 5-fluorouracil in patients with advanced and recurrent renal cell carcinoma. A Southwest Oncology Group Study. Cancer 74 (1994) 916-919
4. Mertens W.C., Eisenhauer E.A., Moore M., et al. Gemcitabine in advanced renal cell carcinoma. A phase II study of the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 4 (1993) 331-332
5. Oevermann K., Buer J., Hoffmann R., et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 83 (2000) 583-587
6. Rini B.I., Vogelzang N.J., Dumas M.C., et al. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer. J Clin Oncol 18 (2000) 2419-2426
7. Motzer R.J., and Russo P. Systemic therapy for renal cell carcinoma. J Urol 163 (2000) 408-417
8. McDermott D.F., Regan M.M., Clark J.I., et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23 (2005) 133-141
9. Yang J.C., Sherry R.M., Steinberg S.M., et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21 (2003) 3127-3132
10. Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353 (1999) 14-17
11. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005;CD001425.
12. Motzer R.J., Bacik J., Murphy B.A., et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
13. Infergen summary of product characteristics. Available at http://www.emea.eu.int/humandocs/Humans/EPAR/infergen/infergen.htm. Accessed 16 November 2006.
14. Herrmann E, Brinkmann OA, Bode ME, et al. Histologic subtype of metastatic renal cell carcinoma predicts response to combined immunochemotherapy with interleukin 2, interferon α and 5-fluorouracil. Eur Urol. In press. doi:10.1016/j.eururo.2006.11.003.
15. Negrier S. Cytokines in metastatic renal cell carcinoma: conclusions from the French PERCY program. Ann Oncol 17 Suppl 9 (2006) ix33 (abstract no. 25IN)
16. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
17. Kaelin Jr. W.G. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2 (2002) 673-682
18. Patard J.-J., Rioux-Leclercq N., and Fergelot P. Understanding the importance of smart drugs in renal cell carcinoma. Eur Urol 49 (2006) 633-643
19. Rini B.I., and Small E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23 (2005) 1028-1043
20. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111 (2003) 1287-1295
21. de Paulsen N., Brychzy A., Fournier M.C., et al. Role of transforming growth factor-alpha in von Hippel- Lindau (VHL)(-/-) clear cell renal carcinoma cell proliferation: a possible mechanism coupling VHL tumor suppressor inactivation and tumorigenesis. Proc Natl Acad Sci USA 98 (2001) 1387-1392
22. Arteaga C.L. Epidermal growth factor receptor dependence in human tumors: more than just expression?. Oncologist 7 Suppl 4 (2002) 31-39
23. Salomon D.S., Brandt R., Ciardiello F., et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19 (1995) 183-232
24. Gollob J.A., Wilhelm S., Carter C., et al. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33 (2006) 392-406
25. Faivre S., Kroemer G., and Raymond E. Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov 5 (2006) 671-688
26. McKillop C. Interview with professor Per-Anders Abrahamson: angiogenesis and renal cell carcinoma. Eur Urol 50 (2006) 609-611
27. Motzer R.J., Amato R., Todd M., et al. Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. Invest New Drugs 21 (2003) 99-101
28. Schwartz G., Dutcher J.P., Vogelzang N.J., et al. Phase 2 clinical trial evaluating the safety and effectiveness of ABX-EGF in renal cell cancer. Proc Am Soc Clin Oncol 21 (2002) 24a (abstract no. 91)
29. Ravaud A., Gardner J., Hawkins R., et al. Efficacy of lapatinib in patients with high tumor EGFR expression: results of a phase III trial in advanced renal cell carcinoma (RCC). J Clin Oncol 24 Suppl. (2006) 217s (abstract no. 4502)
30. ClinicalTrials.gov. Available at www.clinicaltrials.gov. Accessed 7 December 2006.
31. Drucker B., Bacik J., Ginsberg M., et al. Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma. Invest New Drugs 21 (2003) 341-345
32. Wang Y., Fei D., Vanderlaan M., and Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 7 (2004) 335-345
33. Avastin prescribing information. Available at http://www.gene.com/gene/products/information/oncology/avastin/insert.jsp. Accessed 7 December 2006.
34. Yang J.C., Haworth L., Sherry R.M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349 (2003) 427-434
35. Rini B.I., Halabi S., Taylor J., Small E.J., and Schilsky R.L. Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma. Clin Cancer Res 10 (2004) 2584-2586
36. Sutent prescribing information 2005. Available at http://www.pfizer.com. Accessed 20 October 2006.
37. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
38. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
39. Motzer R.J., Hutson T.E., Tomczac P., et al. Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-a) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 Suppl. (2006) 2s (abstract no. LBA3)
40. Kumar R., Harrington L.E., Hooper T.M., et al. Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. J Clin Oncol 23 Suppl 16S (2005) 846s (abstract no. 9537)
41. Hurwitz H., Dowlati A., Savage S., et al. Safety, tolerability and pharmacokinetics of oral administration of GW786034 in patients with solid tumors. J Clin Oncol 23 Suppl 16S (2005) 195s (abstract no. 3012)
42. Hutson T.E., and Bukowski R.M. A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma. Clin Genitourin Cancer 4 (2006) 296-298
43. ClinicalTrials.gov. GW786034 (pazopanib) in metastatic renal cell carcinoma. Available at http://www.clinicaltrials.gov/ct/show/NCT00334282?order=1. Accessed 7 December 2006.
44. Hudes G., Carducci M., Tomczac P., et al. A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC). J Clin Oncol 24 Suppl. (2006) 2s (abstract no. LBA4)
45. Amato R.J., Misellati A., Khan M., et al. A phase II trial of RAD001 in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 Suppl. (2006) 224s (abstract no. 4530)
46. Sorafenib prescribing information. Available at http://www.nexavar.com. Accessed 20 October 2006.
47. Nexavar summary of product characteristics. Available at http://www.emea.eu.int/humandocs/Humans/EPAR/nexavar/nexavar.htm. Accessed 7 December 2006.
48. Ratain M.J., Eisen T., Stadler W.M., et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 2505-2512
49. Escudier B, Szczylik C, Demkow T, et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). Presented at the 42nd American Society of Clinical Oncology Annual Meeting, 2-6 June 2006, Atlanta, GA, USA.
50. Escudier B., Szczylik C., Demkow T., et al. Randomized phase II trial of the multi-kinase inhibitor sorafenib versus interferon (IFN) in treatment naive patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 24 Suppl. (2006) 18s (abstract no. 4501)
51. Escudier B, Eisen T, Stadler W, et al. Sorafenib in advanced clear-cell renal carcinoma. N Engl J Med 356:125-34.